Kinsman et al also conducted a similar intervention on four patients with contraindications to standard therapies including one with recurrent PCa after RT.31 All four patients in the series had undetectable PSA at 3–6 months post-CA and PSA remained undetectable at 12 months for all of the cases. This evidence concerns the gene KLK3 and posterior cortical atrophy.